menu
    • menu
    [{"orgOrder":0,"company":"BirchBioMed","sponsor":"Bionexus Gene Lab","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"DTXCID5040675","moa":"GPR35","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"BirchBioMed","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"BirchBioMed \/ BioNexus Gene Lab","highestDevelopmentStatusID":"9","companyTruncated":"BirchBioMed \/ BioNexus Gene Lab"},{"orgOrder":0,"company":"BirchBioMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DTXCID5040675","moa":"GPR35","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"BirchBioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BirchBioMed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BirchBioMed \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by BirchBioMed

    Menu

    BirchBioMed

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BirchBioMed

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            BirchBioMed

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DTXCID5040675

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Grants BirchBioMed Orphan Drug Designation for FS2 in Idiopathic Pulmonary Fibrosis

                            Details : Kynurenic Acid, a small molecule product targeting GPR35, shows promise in treating Idiopathic Pulmonary Fibrosis (IPF).

                            Product Name : FS2

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2025

                            Lead Product(s) : DTXCID5040675

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BirchBioMed

                            Canada arrow
                            Cell Bio
                            Not Confirmed

                            BirchBioMed

                            Canada arrow
                            Cell Bio
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DTXCID5040675

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Bionexus Gene Lab

                            Deal Size : $10.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bionexus Gene Lab Corp Partners with BirchBioMed Inc.

                            Details : The collaboration aims to advance the clinical development of Kynurenic Acid for targeting GPR35 in the treatment of organ fibrosis.

                            Product Name : FS-2

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 20, 2025

                            Lead Product(s) : DTXCID5040675

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Bionexus Gene Lab

                            Deal Size : $10.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth